GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » EV-to-EBITDA

argenx SE (argenx SE) EV-to-EBITDA : -62.90 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, argenx SE's enterprise value is $19,097 Mil. argenx SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-304 Mil. Therefore, argenx SE's EV-to-EBITDA for today is -62.90.

The historical rank and industry rank for argenx SE's EV-to-EBITDA or its related term are showing as below:

ARGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -122.55   Med: -29.23   Max: 229.41
Current: -62.9

During the past 13 years, the highest EV-to-EBITDA of argenx SE was 229.41. The lowest was -122.55. And the median was -29.23.

ARGX's EV-to-EBITDA is ranked worse than
100% of 473 companies
in the Biotechnology industry
Industry Median: 9.22 vs ARGX: -62.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), argenx SE's stock price is $368.594. argenx SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.150. Therefore, argenx SE's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


argenx SE EV-to-EBITDA Historical Data

The historical data trend for argenx SE's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE EV-to-EBITDA Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.74 -20.00 -40.95 -29.32 -98.88

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.32 -34.03 -41.94 -102.45 -98.88

Competitive Comparison of argenx SE's EV-to-EBITDA

For the Biotechnology subindustry, argenx SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where argenx SE's EV-to-EBITDA falls into.



argenx SE EV-to-EBITDA Calculation

argenx SE's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=19096.557/-303.592
=-62.90

argenx SE's current Enterprise Value is $19,097 Mil.
argenx SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-304 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


argenx SE  (NAS:ARGX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

argenx SE's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=368.594/-5.150
=At Loss

argenx SE's share price for today is $368.594.
argenx SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.150.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


argenx SE EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of argenx SE's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE (argenx SE) Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.